Trial Profile
A double blinded randomised placebo controlled trial of the exelon patch (transdermal rivastigmine) for the treatment of severe delirium in elderly subacute care inpatients.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Delirium
- Focus Therapeutic Use
- Acronyms EPFD1
- 11 May 2015 Status changed from not yet recruiting to discontinued as per Australian New Zealand Clinical Trials Registry.
- 27 Nov 2009 New trial record